Login to Your Account

Earnings Roundup

Friday, November 1, 2013
• Exelixis Inc., of South San Francisco, reported net product revenue for Cometriq (cabozantinib) of $4.8 million in the third quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription